|
Subgroup of compound EGFR mutations
|
Frequency (n, %)
|
Mutated exons
|
Response (rate, %)
|
PFS (range, months)
|
OS (range, months)
|
|---|
|
Double common
|
5 (4.7)
| |
25.0%
|
10.1 ± 2.4
|
24.2 ± 8.2
|
|
19Del + L858R
|
5
|
19 and 21
|
3PR, 1SD, 1PD
|
4.9–12
|
13.1–25.6
|
|
Common + rare
|
11 (10.4)
| |
45.5%
|
10.5 ± 3.9
|
Not reached
|
|
19Del + L861Q
|
2
|
19 and 21
|
1PR, 1SD
|
11.9–14.4
|
26.5–41.2
|
|
L858R + S720P
|
1
|
21 and 18
|
PD
|
2.1
|
2.1
|
|
L858R + K757R
|
1
|
21 and 19
|
PR
|
9.0
|
8.7
|
|
L858R + I744 M
|
1
|
21 and 19
|
PR
|
17.6
|
41.2
|
|
L858R + S768I
|
3
|
21 and 20
|
1PR, 1PD, 1SD
|
1.8–6.2
|
4.0–12.5
|
|
L858R + R776H
|
1
|
21 and 20
|
PR
|
10.5
|
12.6
|
|
L858R + L858Q
|
1
|
21 and 21
|
NE
|
1
|
3
|
|
L858R + L833V
|
1
|
21 and 21
|
SD
|
5.0
|
15.9
|
|
Common + T790M
|
69 (65.1)
| |
56.5%
|
10.3 ± 0.6
|
Not reached
|
|
19Del + T790M
|
43
|
19 and 20
|
27PR, 12SD, 2 PD, 2NE
|
0.6–40.7
|
0.2–88.5
|
|
L858R + T790M
|
26
|
21 and 20
|
12PR, 10SD, 3PD, 1NE
|
0.9–24.1
|
1.2–56.6
|
|
Rare + rare
|
13 (12.3)
| |
38.5%
|
6.5 ± 1.3
|
Not reached
|
|
G719C + S768I
|
1
|
18 and 20
|
PR
|
6.5
|
13.2
|
|
G719S + S768I
|
2
|
18 and 20
|
1PR, 1SD
|
1–8.0
|
2.0–8.4
|
|
G719S + L858Q
|
1
|
18 and 21
|
SD
|
6.4
|
29.3
|
|
G719X + S768I
|
3
|
18 and 20
|
2PR, 1SD
|
2.0–18
|
2.0–44.0
|
|
G719X + L858Q
|
3
|
18 and 21
|
1SD, 1PD, 1NE
|
0.3–27.3
|
2.3–29.2
|
|
G719S + E709A
|
1
|
18 and 18
|
PR
|
4.1
|
4.1
|
|
G719S + L858Q
|
1
|
18 and 21
|
SD
|
6.4
|
29.3
|
|
S768I + V774M
|
1
|
20 and 20
|
PD
|
2.0
|
13.8
|
|
Rare + T790M
|
8 (7.5%)
| |
37.5%
|
5.4 ± 2.5
|
23.8 ± 1.5
|
|
G719X + T790M
|
1
|
18 and 20
|
PR
|
11.1
|
55.6
|
|
D761Y + T790M
|
2
|
19 and 20
|
2PD
|
1.1–5.5
|
1.1–8.5
|
|
L858Q + T790M
|
5
|
21 and 20
|
2PR, 1SD, 2PD
|
1.4–20.6
|
18–88.3
|
- TKI tyrosine kinase inhibitor, PFS progression-free survival, OS overall survival, PR partial response, SD stable disease, CR complete response, PD progressive disease, NE not evaluated
